Dual-specificity tyrosine phosphorylation-regulated kinases (DYRKs) are a type of serine/threonine kinases that are involved in many different cellular processes, such as regulation of incretin-expressing cell number and regulation of GLP-1 expression
However, microdosing is considered an off-label practice with limited clinical research, and professional organizations including the American Diabetes Association do not formally endorse it
Abbreviations AMPK: AMP-activated protein kinase DPP-4: Dipeptidyl peptidase-4 GIP: Glucose-dependent insulinotropic polypeptide GLP-1: Glucagon-like peptide 1 PPAR: Peroxisome proliferator-activated receptor References Nathan DM, Buse JB, Davidson MB et al (2009) Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes
Tirzepatide dosing protocol Tirzepatide follows a well-established escalation schedule refined through multiple clinical trials and years of real-world use: Weeks 1-4: 2.5 mg once weekly (starting dose) Weeks 5-8: 5 mg once weekly Weeks 9-12: 7.5 mg once weekly (optional intermediate step) Weeks 13-16: 10 mg once weekly Weeks 17-20: 12.5 mg once weekly (optional intermediate step) Week 21+: 15 mg once weekly (maximum dose) The starting dose of 2.5 mg is intentionally subtherapeutic
eligibility and terms apply
There are conflicting data on a possible association between GLP-1 use and suicidal ideation
